Weight loss is often viewed as a straightforward equation: burn more calories than you consume. However, the composition of that lost weight matters profoundly. For many people, especially those using GLP-1 medications like semaglutide, a significant portion of the weight lost comes from muscle rather than fat—sometimes up to 30–40% of total weight loss is lean mass. Peptide Treatment in Riyadh This is a problem not just for aesthetics, but for metabolic health, long-term weight maintenance, and physical function. Muscle is metabolically active tissue; losing it slows your resting metabolic rate and makes it easier to regain weight. This is why the next frontier in obesity therapy is not just weight loss, but quality weight loss—fat reduction without muscle loss.
The Muscle Loss Problem with Current Therapies
GLP-1 receptor agonists have revolutionised obesity treatment, but their success has revealed a critical limitation. The STEP 1 trial that led to semaglutide’s approval showed that up to 40% of total weight loss could be attributed to lean body mass reduction . This surpasses the approximately 25% lean mass loss typically seen with standard caloric restriction . The clinical concern is real: an estimated 30% to 40% of GLP-1 RA-associated weight loss may derive from fat-free mass . For older adults or patients with sarcopenic obesity, this muscle loss is particularly concerning .
Next-Generation Peptides: Preserving Muscle While Losing Fat
Emerging research is focused on peptides that can preserve—or even increase—muscle mass during weight loss. Several approaches are in development:
Myostatin/Activin Pathway Blockade
One of the most promising strategies involves blocking GDF8 (myostatin) and activin A, two key regulators of muscle mass. A 2025 study in Nature Communications showed that dual blockade with specific antibodies during GLP-1 treatment in obese mice not only prevented muscle loss but also increased muscle mass and enhanced fat loss . In non-human primates, the combination preserved lean mass while increasing fat loss, offering a potential solution to the muscle-wasting problem of GLP-1 therapy .
Novel Peptide Agonists
Multiple novel peptide candidates are being developed to address the muscle preservation problem:
PTT-A, a unimolecular tetra-agonist targeting GLP-1, GIP, amylin, and calcitonin receptors, demonstrated superior weight loss versus tirzepatide in a 2025 animal study. Critically, PTT-A achieved weight loss through fat loss with no loss of muscle mass, while tirzepatide at the same dose reduced both fat and muscle .
HM17321, a urocortin-2 analog developed by Hanmi Pharmaceutical, selectively activates the CRF2 receptor and is designed to drive fat loss while increasing muscle mass and improving muscle function . The company has received FDA clearance for a Phase 1 study.
Pep19, a synthetic peptide, showed a 17% reduction in visceral fat over 60 days without affecting lean body mass in a triple-blind clinical trial involving 24 obese adults . It also improved sleep quality in all participants .
MD-18, a first-in-class PTP1B-targeting peptide, demonstrated 2.7% weight loss in a Phase 1b trial while maintaining lean muscle mass and improving cardiometabolic markers .
Amino Acid and Peptide Supplementation
For practical use, evidence supports that essential amino acid and peptide-based supplementation can help preserve lean body mass during calorie restriction, particularly when protein intake from whole foods is limited . This aligns with expert guidance that high-quality protein intake and resistance training are core strategies for preserving muscle during GLP-1 therapy .
The Clinical Bottom Line
The shift is clear: the future of obesity treatment is not just about weight loss, but about body composition. As one expert noted, “The problem we see with the GLP that no amount of muscle-stimulating peptides will fix is if a patient is undereating due to GLP-1 effects, the body may still prioritize survival over muscle preservation, even with elevated growth hormone signals” . Peptides are tools, not substitutes for protein, nutrients, hormonal balance, recovery, and strength training .
For those seeking expert guidance on personalised body composition strategies, you can book an appointment consultation at the Enfield Royal Clinic.
Frequently Asked Questions
Can peptides help me lose fat without losing muscle?
Some emerging peptides like PTT-A, HM17321, and Pep19 have shown promise in animal and early human studies for fat loss with muscle preservation. Clinical availability varies.
What is the main cause of muscle loss during weight loss?
Caloric restriction signals the body to conserve energy, leading to muscle breakdown. GLP-1 medications can accelerate this, with up to 40% of weight loss from lean mass.
Do I need to exercise while using peptides for fat loss?
Yes. Resistance training and adequate protein intake are essential for preserving muscle during any weight loss intervention, regardless of peptide use.
Are muscle-preserving peptides FDA-approved?
Most are in early clinical development. GLP-1 medications are FDA-approved, but muscle-preserving adjuncts remain investigational.
What practical steps can I take to preserve muscle during weight loss?
Prioritise protein intake (≥1.6g/kg body weight), engage in resistance training 2-3 times weekly, and avoid overly aggressive calorie deficits.